Gene Vector Market Analysis

Gene Vector Market Analysis

To get key market trends

  Download Free Sample

Based on vector type, the gene vector market is segmented into plasmid DNA, retroviral, lentiviral, adenoviral, adeno-associated viral, and other vectors. The plasmid DNA held largest market share in 2022 and the trend is likely to remain so over the forecast period. There is also an increase in several genetic disorders and numerous life-threatening disorders, especially heart diseases, AIDS, cystic fibrosis, and age-related disorders. Gene therapy with gene vectors provides a complete cure to patients suffering from genetic disorders and other life-threatening disorders rather than ease symptoms with other treatments.
 

Based on application, the gene vector market is segmented into gene therapy, vaccinology, and other applications. The gene therapy accounted for the largest market share in overall market in 2022. This is attributed to the fact that gene therapy is widely used in the treatment for various genetic disorders and inherited disorders. Moreover, continuous technological advancements in developing reliable and safe treatment for different diseases is boosting the growth of this segment.
 

Gene therapy is the advanced treatment applied for cancer, chronic disease, infectious disease, and blood disorders. Gene therapy involves the partial or full replacement of defective genes in a patient's body with healthy ones to treat or prevent disease proliferation.
 

By diseases, the gene vector market is segmented into oncology, genetic disorders, infectious disease, and other diseases. The oncology segment was the largest revenue generating segment in the market in 2022. The upsurge in the global incidence of cancer and modern healthcare facilities are acting as major drivers for the segment growth. According to GLOBOCAN 2020, there were 1,92,92,789 new cancer cases in 2020, and it is projected to increase to 2,88,87,940 cases by 2040. Additionally, there are also many gene therapy strategies that have been developed to treat a wide range of cancers, including suicide gene therapy, oncolytic virotherapy, anti-angiogenesis, and therapeutic gene vaccines.
 

By end user, the gene vector market is segmented into research institutes, CROs, CDMOs, and other end users. The CDMOs segment held the larger market share in 2022. CDMOs engaged in gene and cell therapy research are anticipated to see a growth in demand for gene vectors due to rising investments for the development of gene therapy. organization. In addition, research organizations, CROs, pharmaceutical, and biopharmaceutical companies are the key end users in the gene vectors market, contributing to an increase in the introduction of sophisticated medicines and a growing number of gene therapy-based R&D initiatives.
 

North America dominated the gene vector market with a share of 53.8% in 2022. Some of the major factors that have contributed to the large share of this regional market are the presence of a substantial number of centers and institutes that are engaged in the R&D of advanced gene therapies. Investments made by the federal bodies for the expansion of cell therapy research base in the region are anticipated to enhance the growth of North America market.